Insulin resistance in HIV protease inhibitor-associated diabetes
Contributeurs/tricesYarasheski, K. E.; Tebas, P.; Sigmund, C.; Dagogo-Jack, S.; Bohrer, A.; Turk, J.; Halban, Philippe A.; Cryer, P. E.; Powderly, W. G.
Publié dansJournal of acquired immune deficiency syndromes, vol. 21, no. 3, p. 209-216
Date de publication1999
Résumé
Mots-clés
- Adult
- Animals
- Anti-HIV Agents/ adverse effects/therapeutic use
- C-Peptide/metabolism
- Cells, Cultured
- Cross-Sectional Studies
- Diabetes Mellitus, Type 1/ complications
- Glucagon/metabolism
- HIV Infections/ complications/drug therapy
- HIV Protease Inhibitors/ adverse effects/therapeutic use
- Humans
- Indinavir/ adverse effects/therapeutic use
- Insulin/metabolism
- Insulin Resistance
- Islets of Langerhans/metabolism
- Male
- Phospholipases A/metabolism
- Proinsulin/metabolism
- Rats
- Rats, Sprague-Dawley
Structure d'affiliation
Citation (format ISO)
YARASHESKI, K. E. et al. Insulin resistance in HIV protease inhibitor-associated diabetes. In: Journal of acquired immune deficiency syndromes, 1999, vol. 21, n° 3, p. 209–216.